Clinical trial
Study of an Investigational Drug for the Prevention of Thrombosis-related Events…
NCT00452530 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00452530 |
|---|---|
| Title | Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery |
| Official title | A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery (The ADVANCE - 2 Study) |
| Acronym | ADVANCE-2 |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Deep Vein Thrombosis, Pulmonary Embolism |
| Intervention type | Drug |
| Interventions | Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo |
| Enrollment | 3,221 |
| Start date | Jun 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Mar 27, 2007 |
| Last update posted | Jul 9, 2014 |
| Countries | Austria, Belgium, Brazil, Chile, China, Colombia, Czechia, Denmark, France, Germany, Hungary, India and 15 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: